BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22274798)

  • 21. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S; Gutierrez J; Avisar E
    Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. XRCC1 rs25487 polymorphism predicts the survival of patients after postoperative radiotherapy and adjuvant chemotherapy for breast cancer.
    Tengström M; Mannermaa A; Kosma VM; Hirvonen A; Kataja V
    Anticancer Res; 2014 Jun; 34(6):3031-7. PubMed ID: 24922669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction chemotherapy followed by concurrent chemoradiation in advanced squamous cell carcinoma of the head and neck: final results from a phase II study with docetaxel, cisplatin and 5-fluorouracil with a four-year follow-up.
    Rapidis AD; Trichas M; Stavrinidis E; Roupakia A; Ioannidou G; Kritselis G; Liossi P; Giannakouras G; Douzinas EE; Katsilieris I
    Oral Oncol; 2006 Aug; 42(7):675-84. PubMed ID: 16731029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.
    Manga GP; Shahi PK; Ureña MM; Pereira RQ; Plaza MI; Peron YI; Val RG; Carrión JB; Cañón EP; Alfonso PG
    Breast Cancer; 2010 Jul; 17(3):205-11. PubMed ID: 19551465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
    Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer?
    Massabeau C; Sigal-Zafrani B; Belin L; Savignoni A; Richardson M; Kirova YM; Cohen-Jonathan-Moyal E; Mégnin-Chanet F; Hall J; Fourquet A
    Breast Cancer Res Treat; 2012 Jul; 134(1):259-66. PubMed ID: 22438050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer.
    Chen WC; Kim J; Kim E; Silverman P; Overmoyer B; Cooper BW; Anthony S; Shenk R; Leeming R; Hanks SH; Lyons JA
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):14-20. PubMed ID: 21035961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonsurgical management of esophageal adenocarcinoma.
    Gujral DM; Hawkins MA; Leonulli BG; Ashley S; Chau I; Cunningham D; Tait D
    Clin Colorectal Cancer; 2011 Sep; 10(3):165-70. PubMed ID: 21855037
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concurrent chemoradiotherapy followed by consolidation chemotherapy with bi-weekly docetaxel and carboplatin for stage III unresectable, non-small-cell lung cancer: clinical application of a protocol used in a previous phase II study.
    Saitoh J; Saito Y; Kazumoto T; Kudo S; Yoshida D; Ichikawa A; Sakai H; Kurimoto F; Kato S; Shibuya K
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1791-6. PubMed ID: 21601375
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
    Genet D; Lejeune C; Bonnier P; Aubard Y; Venat-Bouvet L; Adjadj DJ; Martin J; Labourey JL; Benyoub A; Clavère P; Lebrun-Ly V; Juin P; Piana L; Tubiana-Mathieu N
    Br J Cancer; 2007 Oct; 97(7):883-7. PubMed ID: 17876327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
    Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
    Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer.
    Mitsudo K; Shigetomi T; Fujimoto Y; Nishiguchi H; Yamamoto N; Furue H; Ueda M; Itoh Y; Fuwa N; Tohnai I
    Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1428-35. PubMed ID: 20605340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
    White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
    J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gender differences in breast cancer: analysis of 13,000 breast cancers in men from the National Cancer Data Base.
    Greif JM; Pezzi CM; Klimberg VS; Bailey L; Zuraek M
    Ann Surg Oncol; 2012 Oct; 19(10):3199-204. PubMed ID: 22766989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.